share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  09/09 06:15
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a foreign private issuer, has successfully completed the in-life phase of a nine-month non-rodent toxicity study as of September 2024. The study, initiated in November 2023, was conducted in line with discussions with the U.S. Food and Drug Administration (FDA) regarding trial design. The positive outcomes of the study support the regulatory strategy of NeuroSense Therapeutics and affirm the long-term safety profile of its drug candidate, PrimeC. The completion of this phase is a significant milestone for the company and has been documented in the Report on Form 6-K, which is also incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd., a foreign private issuer, has successfully completed the in-life phase of a nine-month non-rodent toxicity study as of September 2024. The study, initiated in November 2023, was conducted in line with discussions with the U.S. Food and Drug Administration (FDA) regarding trial design. The positive outcomes of the study support the regulatory strategy of NeuroSense Therapeutics and affirm the long-term safety profile of its drug candidate, PrimeC. The completion of this phase is a significant milestone for the company and has been documented in the Report on Form 6-K, which is also incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已於2024年9月成功完成了爲期九個月的非齧齒類毒性研究的生命週期階段。該研究於2023年11月啓動,符合與美國食品藥品監督管理局(FDA)關於試驗設計的討論。該研究的積極結果支持NeuroSense Therapeutics的監管策略,並確認了其藥物候選PrimeC的長期安全性。該階段的完成對公司來說是一個重要的里程碑,並已記錄在6-k表格的報告中,該報告也被引用到公司的S-8表格和F-3表格的註冊聲明中。
NeuroSense Therapeutics Ltd.,一家外國私人發行人,已於2024年9月成功完成了爲期九個月的非齧齒類毒性研究的生命週期階段。該研究於2023年11月啓動,符合與美國食品藥品監督管理局(FDA)關於試驗設計的討論。該研究的積極結果支持NeuroSense Therapeutics的監管策略,並確認了其藥物候選PrimeC的長期安全性。該階段的完成對公司來說是一個重要的里程碑,並已記錄在6-k表格的報告中,該報告也被引用到公司的S-8表格和F-3表格的註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息